Relay Therapeutics (RLAY) News Today $3.25 -0.04 (-1.22%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$3.20 -0.05 (-1.57%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Relay Therapeutics, Inc. (NASDAQ:RLAY) Shares Sold by Price T Rowe Associates Inc. MDPrice T Rowe Associates Inc. MD lowered its holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 37.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,321,741 shares of the company's stock after sMay 5 at 4:14 AM | marketbeat.comBoxer Capital Management LLC Acquires Shares of 536,132 Relay Therapeutics, Inc. (NASDAQ:RLAY)Boxer Capital Management LLC bought a new position in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 536,132 shares of the company's stock, valuMay 4 at 6:25 AM | marketbeat.comSusquehanna Fundamental Investments LLC Buys New Stake in Relay Therapeutics, Inc. (NASDAQ:RLAY)Susquehanna Fundamental Investments LLC purchased a new position in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 346,288 shares ofMay 4 at 4:28 AM | marketbeat.comRelay Therapeutics Q1 2025 Earnings PreviewMay 3 at 4:48 AM | msn.comRelay Therapeutics (NASDAQ:RLAY) Shares Down 5.4% - What's Next?Relay Therapeutics (NASDAQ:RLAY) Stock Price Down 5.4% - Should You Sell?May 1, 2025 | marketbeat.comInsider Selling: Relay Therapeutics, Inc. (NASDAQ:RLAY) Insider Sells 10,739 Shares of StockMay 1, 2025 | insidertrades.comAdage Capital Partners GP L.L.C. Sells 250,000 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY)Adage Capital Partners GP L.L.C. decreased its position in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 15.2% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 1,400,000 shares of the company's stock after selling 250,000 shares during theMay 1, 2025 | marketbeat.comRelay Therapeutics to Announce First Quarter 2025 Financial Results and Corporate Highlights on May 5, 2025April 28, 2025 | globenewswire.comRelay Therapeutics (RLAY) Expected to Announce Quarterly Earnings on ThursdayRelay Therapeutics (NASDAQ:RLAY) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 1. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-1-relay-therapeutics-inc-stock/)April 26, 2025 | marketbeat.comInsider Selling: Relay Therapeutics, Inc. (NASDAQ:RLAY) CEO Sells 61,422 Shares of StockApril 25, 2025 | insidertrades.comRelay Therapeutics, Inc. (NASDAQ:RLAY) Stock Position Lifted by Geode Capital Management LLCGeode Capital Management LLC grew its position in Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 10.9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,030,157 shares of the company's stock afterApril 23, 2025 | marketbeat.comRelay Therapeutics, Inc. (NASDAQ:RLAY) Receives Average Recommendation of "Moderate Buy" from BrokeragesShares of Relay Therapeutics, Inc. (NASDAQ:RLAY - Get Free Report) have received a consensus rating of "Moderate Buy" from the eleven brokerages that are presently covering the stock, Marketbeat reports. Two research analysts have rated the stock with a hold recommendation and nine have given a buyApril 22, 2025 | marketbeat.comRenaissance Technologies LLC Grows Position in Relay Therapeutics, Inc. (NASDAQ:RLAY)Renaissance Technologies LLC grew its stake in Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 130.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,549,190 shares of the cApril 21, 2025 | marketbeat.comFranklin Resources Inc. Sells 1,338,037 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY)Franklin Resources Inc. lessened its position in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 95.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 58,805 shares of the company's stock aftApril 21, 2025 | marketbeat.comRelay Therapeutics (RLAY): The Most Promising Penny Stock According to AnalystsApril 20, 2025 | insidermonkey.comRelay Therapeutics (NASDAQ:RLAY) Coverage Initiated by Analysts at Wells Fargo & CompanyWells Fargo & Company assumed coverage on Relay Therapeutics in a research report on Thursday. They issued an "equal weight" rating and a $4.00 price objective on the stock.April 19, 2025 | marketbeat.comWalleye Capital LLC Has $3.82 Million Stake in Relay Therapeutics, Inc. (NASDAQ:RLAY)Walleye Capital LLC decreased its holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 49.1% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 927,137 shares of the company's stock after selling 892,846 shares dApril 19, 2025 | marketbeat.comWells Fargo Initiates Coverage of Relay Therapeutics (RLAY) with Equal-Weight RecommendationApril 18, 2025 | msn.comRelay Therapeutics initiated with an Equal Weight at Wells FargoApril 17, 2025 | markets.businessinsider.comIs Relay Therapeutics Inc. (NASDAQ:RLAY) the Best Biotech Penny Stock to Buy According to Hedge Funds?April 16, 2025 | msn.comVanguard Group Inc. Acquires 566,595 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY)Vanguard Group Inc. increased its holdings in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 3.9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 15,030,209 shares of the company's stockApril 14, 2025 | marketbeat.comJPMorgan Chase & Co. Has $20.51 Million Stock Holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY)JPMorgan Chase & Co. reduced its stake in Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 9.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,978,443 shares of the company's stock afApril 13, 2025 | marketbeat.comRelay Therapeutics: Trying To Find That Right PriceApril 12, 2025 | seekingalpha.comRelay Therapeutics, Inc. (RLAY): Among Stocks Under $10 that Will TripleApril 9, 2025 | msn.comFinepoint Capital LP Buys 549,500 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY)Finepoint Capital LP grew its stake in Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 33.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,175,646 shares of the company's stock after purchasing an additionApril 8, 2025 | marketbeat.comNorges Bank Takes $23.82 Million Position in Relay Therapeutics, Inc. (NASDAQ:RLAY)Norges Bank acquired a new position in Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 5,781,878 shares of the company's stock, valued at approximately $23,821,00April 8, 2025 | marketbeat.comTrexquant Investment LP Purchases 566,275 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY)Trexquant Investment LP grew its position in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 137.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 978,137 shares of the company's stock after buying an aApril 7, 2025 | marketbeat.comRaymond James Financial Inc. Invests $779,000 in Relay Therapeutics, Inc. (NASDAQ:RLAY)Raymond James Financial Inc. bought a new stake in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 189,046 shares of the company's stock, valued at approximatelApril 7, 2025 | marketbeat.comCancer drug developer cuts staff for the third time in a yearApril 5, 2025 | bizjournals.comRelay Therapeutics, Inc. (NASDAQ:RLAY) Shares Acquired by Prudential Financial Inc.Prudential Financial Inc. raised its stake in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 45.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 549,645 shares of the company's stock after buying an additional 173,0April 5, 2025 | marketbeat.comRelay TherapeuticsApril 3, 2025 | forbes.comRelay Therapeutics’ SWOT analysis: promising drug data boosts stock outlookApril 2, 2025 | investing.comRelay Therapeutics, Inc. (NASDAQ:RLAY) CFO Thomas Catinazzo Sells 4,864 SharesRelay Therapeutics, Inc. (NASDAQ:RLAY - Get Free Report) CFO Thomas Catinazzo sold 4,864 shares of the firm's stock in a transaction dated Thursday, March 27th. The stock was sold at an average price of $2.84, for a total transaction of $13,813.76. Following the transaction, the chief financial officer now directly owns 374,567 shares in the company, valued at approximately $1,063,770.28. This represents a 1.28 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.April 1, 2025 | marketbeat.comRelay Therapeutics, Inc. (NASDAQ:RLAY) CFO Sells $13,813.76 in StockApril 1, 2025 | insidertrades.comRelay Therapeutics (RLAY) Gets Analyst Boost as AI-Driven Drug Discovery Shines!March 31, 2025 | msn.comRelay Therapeutics weakness brings buying opportunity, says BarclaysMarch 28, 2025 | markets.businessinsider.comRelay Therapeutics (NASDAQ:RLAY) Trading 6.1% Higher - Should You Buy?Relay Therapeutics (NASDAQ:RLAY) Shares Up 6.1% - Still a Buy?March 28, 2025 | marketbeat.comBIT Capital GmbH Acquires New Holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY)BIT Capital GmbH bought a new position in Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund bought 284,508 shares of the company's stock, valued at approximately $1,172,000. BIT Capital GmbH owneMarch 28, 2025 | marketbeat.comRelay Therapeutics, Inc. (NASDAQ:RLAY) Given Consensus Recommendation of "Moderate Buy" by BrokeragesRelay Therapeutics, Inc. (NASDAQ:RLAY - Get Free Report) has earned an average recommendation of "Moderate Buy" from the ten research firms that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation and nine have assigned a buy recommeMarch 27, 2025 | marketbeat.comRelay Therapeutics (NASDAQ:RLAY) Sets New 52-Week Low - What's Next?Relay Therapeutics (NASDAQ:RLAY) Hits New 52-Week Low - Should You Sell?March 26, 2025 | marketbeat.comRelay Therapeutics (NASDAQ:RLAY) Shares Down 3.2% - Should You Sell?Relay Therapeutics (NASDAQ:RLAY) Shares Down 3.2% - What's Next?March 20, 2025 | marketbeat.comRelay Therapeutics’ SWOT analysis: promising drug faces stiff competitionMarch 19, 2025 | investing.comRelay Therapeutics (NASDAQ:RLAY) Trading Down 6.7% - Should You Sell?Relay Therapeutics (NASDAQ:RLAY) Shares Down 6.7% - Here's What HappenedMarch 14, 2025 | marketbeat.comRelay Therapeutics’ SWOT analysis: stock poised for growth amid challengesMarch 14, 2025 | investing.comHC Wainwright Reaffirms Buy Rating for Relay Therapeutics (NASDAQ:RLAY)HC Wainwright reiterated a "buy" rating and set a $16.00 target price on shares of Relay Therapeutics in a report on Friday.March 8, 2025 | marketbeat.comCandriam S.C.A. Acquires 636,494 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY)Candriam S.C.A. lifted its holdings in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 58.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,729,199 shares of the compMarch 8, 2025 | marketbeat.comRelay Therapeutics (NASDAQ:RLAY) Hits New 1-Year Low - Should You Sell?Relay Therapeutics (NASDAQ:RLAY) Sets New 52-Week Low - Here's WhyMarch 6, 2025 | marketbeat.comRelay Therapeutics (NASDAQ:RLAY) Shares Down 8.1% - Here's WhyRelay Therapeutics (NASDAQ:RLAY) Trading Down 8.1% - Here's WhyMarch 4, 2025 | marketbeat.comRelay Therapeutics price target lowered to $12 from $21 at Citizens JMPFebruary 28, 2025 | markets.businessinsider.comBank of America Securities Sticks to Their Buy Rating for Relay Therapeutics (RLAY)February 28, 2025 | markets.businessinsider.com Get Relay Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RLAY and its competitors with MarketBeat's FREE daily newsletter. Email Address RLAY Media Mentions By Week RLAY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RLAY News Sentiment▼0.450.73▲Average Medical News Sentiment RLAY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RLAY Articles This Week▼125▲RLAY Articles Average Week Get Relay Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RLAY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AAPG News KYMR News CGON News MTSR News MIRM News BHC News BEAM News NAMS News VCEL News BLTE News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RLAY) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredDonald Trump is about to free crypto from its chains …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Relay Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Relay Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RLAY Stock Free RLAY Stock Alerts